

CURRENT STATUS OF CLAIMS WITH CLAIM AMENDMENTS

1-20. **(Canceled)**

21. **(Withdrawn)** A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:

(a) obtaining a sample from said individual;
(b) measuring a test expression level of PAMP polypeptide by contacting a cell, a cell lysate, or fractionated sample thereof, from said individual with a binding agent selective for PAMP polypeptide residues 1 to 1074 of SEQ ID NO:2, and determining the amount of selective binding of said agent; and

(c) comparing said test expression level of PAMP polypeptide to a control expression level of PAMP polypeptide, wherein a test expression level 2-fold or more greater than said control expression level indicates the presence of a prostate neoplastic condition.

22. **(Withdrawn)** The method of claim 21, wherein said binding agent selective for said PAMP polypeptide residues 1 to 1074 of SEQ ID NO:2 comprises an antibody.

23. **(Withdrawn)** The method of claim 22, wherein said binding agent further comprises a detectable label.

24. **(Canceled)**

25. **(Canceled)**

Inventor: Biaoyang Lin
Serial No.: 09/729,653
Filed: December 4, 2000
Page 3

26. **(Previously presented)** An isolated PAMP polypeptide, comprising the amino acid sequence shown as SEQ ID NO: 2 or an amino acid sequence having one or more conservative substitutions relative to SEQ ID NO: 2.

27. **(Previously presented)** The isolated PAMP polypeptide of claim 26, comprising the amino acid sequence shown as SEQ ID NO:2.

28. **(Canceled)**

29. **(Canceled)**

30. **(New)** The method of claim 21, wherein said binding agent is a monoclonal antibody.

31. **(New)** The method of claim 21, wherein said binding agent is a polyclonal antibody.

32. **(New)** The method of claim 21, wherein said sample is a serum sample.